Combined use of cetuximab and chemotherapy in recurrent or metastatic squamous cell carcinoma of head and neck
10.3760/cma.j.issn.1673-422X.2010.12.009
- VernacularTitle:西妥昔单抗联合化疗在复发或转移头颈部鳞状细胞癌中的应用
- Author:
Shuai XIAO
- Publication Type:Journal Article
- Keywords:
Antibodies,monoclonal;
Head and neck neoplasms;
Carcinoma,squamous cell;
Drug therapy
- From:
Journal of International Oncology
2010;37(12):907-909
- CountryChina
- Language:Chinese
-
Abstract:
Recurrent or metastatic squamous cell carcinoma of the head and neck(SCCHN) has a poor prognosis. Cetuximab is a monoclonal antibody that inhibits epidermal growth factor receptor (EGFR) and improves the effect of several chemotherapeutical agents including cisplatin. Several clinical trials have shown that cetuximab combined with chemotherapy was effective and well tolerated for the treatment of recurrent or metastatic SCCHN. The strengths of such treatment are its high efficacy and low toxicity.
